Korean Government Fines Five Pharma Multinationals For Unfair Trade
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's trade watchdog, the Fair Trade Commission, has imposed fines collectively totaling KRW 20.48 billion ($14.8 million) on seven pharmaceutical companies - including five multinationals - on charges of unfair provision of rebates and other improper benefits to doctors and hospitals
You may also be interested in...
Korea's Antitrust Watchdog Says Rebates Continuing Despite New Law; Levies $11 Million In Fines
SEOUL - South Korea's antitrust watchdog the Fair Trade Commission said rebates by both multinational and local Korean pharmaceutical companies are continuing even though doctors can be punished for accepting rebates under a new law that took effect late last year
Korea's Antitrust Watchdog Says Rebates Continuing Despite New Law; Levies $11 Million In Fines
SEOUL - South Korea's antitrust watchdog the Fair Trade Commission said rebates by both multinational and local Korean pharmaceutical companies are continuing even though doctors can be punished for accepting rebates under a new law that took effect late last year
Four Major South Korean Hospitals Are Penalized For Soliciting "Donations" From Pharmaceutical Outfits Including MNCs
SEOUL - In the latest government action against irregular business deals in the medical sector, South Korea's Fair Trade Commission has imposed penalties amounting to KRW550 million (about $484,282) on the country's four leading general hospitals for receiving "donations" from 14 local and international pharmaceutical firms to fund expansion projects